The U.S. Army has awarded a sole source contract to GE Healthcare Bio-sciences Corp for highly specialized biological reagents for the production of a genetically derived ricin A chain vaccine candidate (RVCe).
This second cGMP production lot of the RVEc ricin vaccine will be produced at the University of Nebraska-Lincoln Biological Process Development Facility (UNL-BPDF), using the same personnel, facilities and equipment employed in the production the first vaccine lot.
“In conjunction with this process continuity, and to minimize any batch-to-batch variability in the RVEc production lots, the requested supplies are identical to the specific bio-processing reagents used in the production of the first cGMP production lot of the Army’s RVEc vaccine in 2010,” states the Army award justification.
This second vaccine lot will be used in FDA-sponsored human clinical trials, according to the announcement.
Source: FBO.gov
